Nautilus Biotechnology Inc
NAUT
Company Profile
Business description
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Contact
2701 Eastlake Avenue East
SeattleWA98102
USAT: +1 206 333-2001
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
130
Stocks News & Analysis
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
stocks
Undervalued supermarket share sees sales improvement
Improving sales trends but recovery remains gradual.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,927.30 | 7.10 | 0.08% |
| CAC 40 | 8,179.77 | 63.01 | 0.78% |
| DAX 40 | 25,568.56 | 207.41 | 0.82% |
| Dow JONES (US) | 52,573.29 | 509.19 | 0.98% |
| FTSE 100 | 10,650.44 | 41.52 | 0.39% |
| HKSE | 24,721.55 | 84.08 | -0.34% |
| NASDAQ | 26,333.04 | 251.31 | 0.96% |
| Nikkei 225 | 63,395.35 | 615.99 | -0.96% |
| NZX 50 Index | 13,654.76 | 74.43 | 0.55% |
| S&P 500 | 7,656.98 | 65.28 | 0.86% |
| S&P/ASX 200 | 8,749.60 | 8.40 | 0.10% |
| SSE Composite Index | 3,878.60 | 9.51 | -0.24% |